Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

(MedPage Today) — The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the market…

Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/119806

Author :

Publish date : 2026-02-09 20:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

Non-Sterile Wipes Tied to Fatal Infection, Officials Say

Nurses Say They Might Return to Hospitals If Employers Made These Changes

Related Posts

Arranging social care can be “horrendous”, Baroness Casey tells BBC

AI Tool Could Help Identify Osteoporosis and Osteopenia Risk

PIP Matches PrEP for Low-Risk HIV

Semaglutide for Alzheimer’s: What the EVOKE Trials Taught Us

Could Red Light Help Tackle Resistant Klebsiella Pneumoniae?

Verekitug Improved Chronic Rhinosinusitis With Nasal Polyps

Arranging social care can be “horrendous”, Baroness Casey tells BBC

AI Tool Could Help Identify Osteoporosis and Osteopenia Risk

PIP Matches PrEP for Low-Risk HIV

Semaglutide for Alzheimer’s: What the EVOKE Trials Taught Us

Could Red Light Help Tackle Resistant Klebsiella Pneumoniae?

Verekitug Improved Chronic Rhinosinusitis With Nasal Polyps

Death of boy after surgery is referred to coroner

After FDA Declined Review, EMA Backs 1st Flu-COVID mRNA Vax

Categories

Archives